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Abstract 
Background: Type 2 diabetes mellitus (T2DM) is a chronic and multifactorial disease with a rapidly rising incidence 
in Saudi Arabia. Various genes including zinc finger protein 1 (JAZF1) and tetraspanin 8/leucine‑rich repeat‑containing 
G protein‑coupled receptor (TSPAN8/LGR5) have been previously described to be associated with T2DM. This study 
investigated the association of JAZF1 (rs864745) and TSPAN8 (rs7961581) with T2DM in a Saudi population.
Methods: Genomic DNA samples from 400 Saudi T2DM patients and 400 healthy controls were genotyped and ana‑
lyzed using a polymerase chain reaction‑restriction fragment length polymorphism method. The difference between 
the genotype frequencies were carried out with Chi‑square test. Odds ratio, 95 % confidence intervals and p values 
were calculated using multinomial logistic regression. Dominant and recessive models were implemented to show 
the statistical significances. Analysis of variance was used to compare differences between genotypes for the various 
parameters.
Results: Distribution frequencies of the AA, AG, and GG genotypes of JAZF1 (rs864745) differed significantly among 
T2DM patients and healthy controls (p < 0.05). The AG and GG genotypes were independently and significantly 
associated with a T2DM risk after adjusting for factors such as age, sex, and body mass index [odds ratio (OR) 2.1 
(95 % confidence interval (CI) 1.3–3.4); p = 0.002] and [OR 1.9 (95 % CI 1.2–3.1); p = 0.005], respectively. A genotype‑
based stratification of anthropometric and biochemical data revealed that the AG + GG genotype is associated with 
waist circumference (p = 0.04) and fasting blood glucose (p = 0.01) and high‑density lipoprotein cholesterol levels 
(p = 0.02). None of the allele or genotype showed the significant association between the T2DM cases and control 
subjects in rs7961581 polymorphism in TSPAN8/LGR5 gene.
Conclusion: The rs864745 variant in JAZF1 gene may act as genetic risk factors for the development of T2DM in a 
Saudi population.
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Background
Type 2 diabetes mellitus (T2DM) is a multifactorial 
and common chronic metabolic disease that is a major 
public health concern in many countries including 
the Arab population [1]. An estimated number of 285 
million people are currently diabetic worldwide, and this 
is expected to increase up to 438 million by the year 2030. 
[2–4]. Worldwide, Saudi Arabia ranks seventh in T2DM 
prevalence and the incidence of this disease has doubled 
over the last two decades in the kingdom [1]. Several 
risk factors such as obesity, hypertension, undesirable 
lipid profiles, and increased fasting glucose levels as well 
as a parental history of diabetes contributes the predis-
position for T2DM development [5]. Besides lifestyle 
factors and other environmental parameters which are 
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partially responsible for the increased T2DM incidence, 
also genetic risk factors were shown to contribute [6]. 
The increased incidence of T2DM and the importance of 
early detection and management have prompted investi-
gations to identify environmental and genetic factors that 
increase T2DM, risk and the related complications [7].
New insights into the genetic risk for T2DM include 
variants of the genes juxtaposed with another zinc finger 
protein 1 (JAZF1) and tetraspanin 8/leucine-rich repeat-
containing G protein-coupled receptor (TSPAN8/LGR5) 
[7–9]. Numerous replication studies have indicated that 
JAZF1 and TSPAN8/LGR5 affect various aspects of β-cell 
function [9–13].
The rs864745 variant in JAZF1 and rs7961581 variant 
in TSPAN8/LGR5 are significantly associated with insu-
lin secretion and glucose-tolerance [14] and T2DM risk 
[9, 15]. However, there is limited information available on 
possible association of rs864745 (JAZF1) and rs7961581 
(TSPAN8/LGR5) polymorphism with T2DM susceptibil-
ity in Saudi population. Therefore, in this case–control 
study, we tested whether the polymorphisms in JAZF1 
(rs864745) and TSPAN8/LGR5 (rs7961581) represents an 
additional risk factor for T2DM.
Methods
Patient selection
A total of 800 Saudi subjects (400 T2DM patients and 
400 healthy controls) belonging to the same demographic 
area were enrolled in this study as described previously 
[16]. T2DM diagnosis was based on the criteria of World 
Health Organization (fasting glucose level ≥126  mg/
dL or >7.0  mmol/L). A generalized questionnaire was 
administered to all consenting subjects and included 
demographics and past medical history. The subjects 
with other medical complications such as coronary artery 
disease, nephropathy, thyroid, and liver or end stage renal 
diseases were excluded from this study. Healthy volun-
teers (n = 400) with normal fasting blood glucose levels 
were selected from the general population based on age 
and gender. From the total recruited subjects 88.5  % of 
the T2DM and 52.5  % of the controls had a family his-
tory of T2DM. The study was approved by the local eth-
ics committee [1, 5].
Sample collection
Five milliliters (mL) of over-night fasting blood samples 
were obtained, 2  mL were collected in ethylenediamine 
tetra acetic acid (EDTA) tubes (used for molecular analy-
sis) and the other 3 mL in serum separator tubes.
Clinical and biochemical estimations
Clinical and anthropometric parameters, including blood 
pressure (mmHg), weight (kg), height (m), and hip (cm) 
and waist (cm) circumferences were measured using 
standard procedures [17]. Body mass index (BMI) was 
calculated as weight/height2 (kg/m2). Fasting blood glu-
cose (FBG) and lipid profile [triglyceride (TG), total cho-
lesterol (TC), and high-density lipoprotein cholesterol 
(HDL-C)] were measured using a chemistry auto-ana-
lyzer and commercially available kits (Konelab, Finland). 
Low-density lipoprotein cholesterol (LDL-C) concentra-
tions were calculated using Friedwald’s formula. Insulin 
was quantified by a solid phase enzyme amplified sensi-
tivity immunoassay (Medgenix INS-ELISA, Biosource, 
Belgium). Homeostasis model assessment for insulin 
resistance (HOMA-IR) was calculated as follows = insu-
lin (μU/mL)  ×  glucose (mmol/L)/22.5. Dyslipidemia 
(low levels of HDL-C) was defined as an HDL-C level of 
<1.03 mmol/L for men and <1.29 mmol/L for women [5, 
16, 17].
DNA extraction
Genomic DNA was isolated from whole blood using a 
standard DNA extraction kit (Norgen Biotek Corp., Can-
ada). The quality and quantity of DNA were examined 
using Nanodrop and gel electrophoresis. DNA was stored 
at −80 °C.
Analysis of polymorphisms
In this study, we have opted 2 genetic variants, such as 
JAZF1 (rs864745) and TSPAN8/LGR5 (rs7961581) for 
performing the molecular analysis based on previous lit-
erature studies with higher minor allele frequency (MAF) 
[9, 11–13]. Genotyping was carried out using the poly-
merase chain reaction-restriction fragment length poly-
morphism (PCR–RFLP) method. For rs864745 (A  >  G), 
primers 5′-GAGCCATATAAGTGATGCTCAAA-3′ 
(sense) and 5′-GGTTGTCAGGCTTTCCATGT-3′ (anti-
sense) were used to amplify a 378-bp DNA fragment, 
whereas for rs7961581 (T  >  C), primers 5′-TGGCATC 
CAGCTTGTTATTG-3′ (sense) and 5′-TGAGAGCACT 
GTGTGTGTCACT-3′ (antisense) were used to amplify a 
243-bp DNA fragment. PCRs were performed in a ther-
mal cycler with initial denaturation at 95  °C for 5  min, 
followed by 35 cycles of denaturation at 95  °C for 30  s, 
annealing 58 °C for 30 s, and extension at 72 °C for 45 s. 
For rs864745, the PCR product (15 µL) was digested with 
2U SSPI restriction endonuclease (New England Bio 
Labs, UK) for 16  h at 37  °C. The 378-bp (A allele) PCR 
product was cleaved into 338 and 40-bp fragments in the 
presence of a G allele (rare), but not in its absence. For 
rs7961581 polymorphisms, 15 µL of PCR product was 
digested with 4U Hpy16611 (New England Bio Labs) for 
18 h at 37  °C, producing fragments of 210 and 33 bp in 
the case of a polymorphic variant (allele C) and T allele 
(243  bp) represents homozygous variant. All digested 
Page 3 of 7Alharbi et al. Diabetol Metab Syndr  (2015) 7:92 
fragments were directly analyzed by polyacrylamide gel 
electrophoresis and visualized after silver staining [18].
Statistical analysis
Statistical analyses were performed using SPSS version 
19.0 for Windows (SPSS Inc., Chicago, IL, USA). All con-
tinuous variables were presented as mean  ±  standard 
deviation. An independent sample T test was used to 
compare the control and T2DM groups. Significant dif-
ferences were defined as p  <  0.05. Genotype frequency 
differences between patients and controls for each sin-
gle nucleotide polymorphisms (SNPs) were tested using 
Chi square test. Odds ratios (ORs) and 95 % confidence 
intervals (95  % CIs) were calculated using multinomial 
(multiple) logistic regression with the wild type as the 
reference. Variables such as age, gender and BMI were 
included in the multinomial logistic model. Analysis of 
variance (ANOVA) was used to compare differences 
between genotypes for the various parameters. Chi-
square test was used to identify departures from Hardy–
Weinberg equilibrium.
Results
Clinical and anthropometric data of subjects are shown 
in Table 1. Subjects with T2DM were significantly older 
and had higher BMI, waist and hip circumferences, sys-
tolic and diastolic blood pressure, and FBG, TG, and TC 
levels and lower HDL-C levels than control subjects.
Genotype distribution
Distribution of genotypes and allele frequencies of the 
rs864745 (JAZF1) polymorphism in patients and con-
trols were in accordance with the Hardy–Weinberg equi-
librium (p  >  0.05), but not rs7961581 (TSPAN8/LGR5) 
(p < 0.01). The estimated powers of the study were 86 and 
12.2  % (at desired significance level 0.05) for rs864745 
and rs7961581, respectively.
Table 2 displays the genotype distribution for rs864745 
and rs7961581 among the T2DM and control subjects. 
The distributions of the AA, AG, and GG genotypes 
(p < 0.005) and the AG + GG genotype (p < 0.0001) of 
rs864745 differed significantly between T2DM and 
control subjects. Likewise, the frequency AA geno-
type occurrence (rs864745) was significantly higher in 
the controls than the T2DM group (47.25 vs. 34.25  %), 
whereas the occurrence of the AG and GG genotypes 
was significantly higher in the T2DM group than controls 
(41.25 vs. 46.5 % for AG; 11.5 vs. 19.25 % for GG). No dif-
ference was observed between groups in the genotypic 
distribution of the rs7961581 variant.
We next determined the association of AG, GG, and 
AG + GG genotypes of rs864745 with T2DM risk, with 
AA as the (wild type) reference genotype (Table  2). 
Occurrence of the AG, GG, and AG  +  GG genotypes 
was associated with increased T2DM risk [ORs 1.5 (95 % 
CI 1.2–2.1, p = 0.004); 2.2 (95 % CI 1.4–3.4, p < 0.0001), 
and 1.7 (95  % CI  1.2–2.1, p  <  0.0001), respectively]. No 
association was found for the rs7961581 variants (p > 0. 
05). We next evaluated the association between JAZF1 
or TSPAN8/LGR5 variants and T2DM risk using mul-
tiple logistic regression analysis for independence after 
controlling for other risk factors such as age, gender, and 
BMI. A significant association was detected for the AG, 
GG, and AG + GG genotypes of rs864745 (ORs 2.1 (95 % 
CI 1.3–3.4, p = 0.002); 1.9 (95 % CI 1.2–3.1, p = 0.005), 
and 2.0 (95 % CI 1.3–3.2), p = 0.001, respectively). Con-
versely, no effect of rs7961581 on T2DM susceptibility 
was observed.
Table 3 shows the stratification of the genotype distri-
bution for the rs864745 and rs7961581 variants based 
on gender. The AG and AG  +  GG variants of JAZF1 
(rs864745) were consistently associated with increased 
T2DM risk in both female [AG: OR 2.0 (95 % CI 1.2–3.9), 
p = 0.02); AG + GG: OR 1.9 (95 % CI 1.1–3.6), p = 0.03] 
and male subjects (AG: OR 1.8 (95  % CI  1.0–3.1), 
p = 0.04; AG + GG: OR 1.7 (95 % CI 1.0–2.9), p = 0.03). 
This effect remained significant only in males (p < 0.01) 
even after adjusting for age and BMI. Finally, the gen-
der-based stratification of the genotype distribution for 
rs7961581 suggested that the association with T2DM 
is driven by male gender. The association remained sig-
nificant even after adjusting for age and BMI (TC: OR 
Table 1 Epidemiologic, anthropometric and  metabolic 
characterization of the individuals enrolled in the study
SBP systolic blood pressure, DBP diastolic blood pressure, FBG fasting blood 
glucose
T2DM (n = 400) Controls (n = 400) p value
Age (years) 53.6 ± 10.8 46.06 ± 7.7 <0.001
Sex (male/female) 232/168 211/189 0.13
Body mass index  
(kg/m2)
30.7 ± 6.3 29.2 ± 5.5 0.001
Waist (cm) 94.5 ± 22.2 91.6 ± 19.9 0.02
Hip (cm) 110.79 ± 18.2 101.46 ± 7.80 0.001
SBP (mmHg) 124.3 ± 11.2 114.9 ± 7.7 <0.001
DBP (mmHg) 78.4 ± 6.9 75.6 ± 6.0 <0.001
FBG (mmol/L) 12.9 ± 4.6 5.25 ± 0.59 <0.001
Triglycerides (mmol/L) 2.23 ± 1.2 1.61 ± 0.86 <0.001
Cholesterol (mmol/L) 5.6 ± 1.2 5.1 ± 0.98 <0.001
HDL‑cholesterol 
(mmol/L)
0.83 ± 0.36 0.63 ± 0.22 <0.001
LDL‑cholesterol 
(mmol/L)
3.8 ± 1.0 3.68 ± 0.85 0.18
Insulin (µU/mL) 16.2 ± 2.2 12.3 ± 1.7 0.006
HOMA‑IR 7.12 ± 2.4 2.87 ± 1.7 <0.0001
Family history 354 (88.5 %) 210 (52.5 %) <0.0001
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1.8 (95 % CI 1.1–2.9), p = 0.01; TC + CC: OR 1.7 (95 % 
CI 1.1–2.6), p = 0.01).
Association of JAZF1 and TSPAN8/LGR5 variants 
with metabolic parameters
 To study the effects of JAZF1 and TSPAN8/LGR5 poly-
morphisms on the different clinical parameters, we ana-
lyzed the distribution of these variables in relation to the 
various genotypes. Compared with the AA genotype, 
the AG + GG genotype subjects had significantly higher 
waist circumference (93.8  ±  20.4 vs. 89.8  ±  22.1  cm, 
p  =  0.04), FBG (9.3  ±  5.1 vs. 8.0  ±  4.7  mmol/L, 
p = 0.01) and lower HDL-C concentration (0.72 ± 0.31 
vs. 0.79  ±  0.34  mmol/L, p  =  0.02; Table  4). No such 
associations were found for the rs7961581 polymor-
phism, for any of the variables examined Table 5. 
Discussion
To the best of our knowledge, the association between 
the JAZF1 (rs864745) or TSPAN8/LGR5 (rs7961581) 
polymorphisms and T2DM has not been reported in 
Arab populations, particularly in Saudi Arabia, despite an 
increased prevalence and incidence of T2DM. The pre-
sent study is the first to examine the interaction between 
silent substitutions with no alteration in amino acids 
and provides preliminary information on the associa-
tion between JAZF1 or TSPAN8/LGR5 polymorphisms 
and T2DM risk. Additionally, the AG + GG genotype of 
Table 2 The genotype distribution of rs864745 (JAZF1) and rs796158 (TSPAN8/LGR5) polymorphisms in T2DM and con-
trol group
a Crude odds ratio (95 % CI)
b Odds ratio (95 % CI) controlled for age, gender and BMI
Control n (%) T2DM n (%) Odds ratioa (95 % CI) p value Odds ratiob (95 % CI) p value
JAZF1 (rs864745)
 AA 189 (47.25) 137 (34.25) Reference Reference
 AG 165 (41.25) 186 (46.5) 1.5 (1.2, 2.1) 0.004 2.1 (1.3, 3.4) 0.002
 GG 46 (11.5) 77 (19.25) 2.2 (1.4, 3.4) 0.0001 1.9 (1.2, 3.1) 0.005
 AG + GG 211 (52.75) 263 (65.75) 1.7 (1.2, 2.1) 0.0001 2.0 (1.3, 3.2) 0.001
 AA + AG 354 (89.5) 323 (80.75) 0.5 (0.3, 0.8) 0.002 0.8 (0.4, 1.5) 0.003
TSPAN8 (rs7961581)
 CC 63 (15.8) 55 (13.8) 0.90 (0.59, 1.4) 0.63 1.0 (0.66, 1.6) 0.86
 TC 138 (34.4) 153 (38.2) 1.1 (0.84, 1.4) 0.37 1.2 (0.82, 1.6) 0.41
 TT 199 (49.8) 192 (48.0) Reference Reference
 CC + TC 201 (50.2) 208 (52.0) 1.07 (0.81, 1.4) 0.72 1.1 (0.82, 1.5) 0.47
 TT + TC 337 (84.2) 345 (86.2) 1.1 (0.79, 1.73) 0.42 1.1 (0.81, 1.75) 0.38
Table 3 The genotype distribution of rs864745 (JAZF1) and rs796158 (TSPAN8/LGR5) polymorphisms in T2DM and con-
trol group stratified based gender
a Crude odds ratio (95 % CI);
b Odds ratio (95 % CI) controlled for age and BMI
Males Females
Odds Ratio (95 % CI)a p value Odds ratio (95 % CI)b p value Odds Ratio (95 % CI)a p value Odds ratio (95 % CI)a p value
JAZF1 (rs864745)
 AA Reference Reference
 AG 2.0 (1.1, 3.9) 0.02 2.0 (1.0, 4.0) 0.04 1.8 (1.0, 3.1) 0.04 2.2 (1.1, 4.3) 0.01
 GG 1.8 (0.96, 3.5) 0.06 1.7 (0.87, 3.5) 0.11 1.7 (0.98, 3.0) 0.05 2.2 (1.2, 4.2) 0.01
 AG + GG 1.9 (1.1, 3.6) 0.03 1.9 (0.99, 3.6) 0.05 1.7 (1.0, 2.9) 0.03 2.2 (1.2, 4.1) 0.008
TSPAN8 (rs7961581)
 CC 0.64 (0.33, 1.2) 0.19 0.72 (0.36, 1.4) 0.35 1.1 (0.66, 1.9) 0.62 1.4 (0.76, 2.5) 0.27
 TC 0.74 (0.47, 1.2) 0.21 0.69 (0.42, 1.1) 0.14 1.6 (1.1, 2.4) 0.02 1.8 (1.1, 2.9) 0.01
 TT Reference Reference Reference Reference
 CC + TC 0.72 (0.47, 1.1) 0.12 0.70 (0.45, 1.1) 0.12 1.5 (1.0, 2.1) 0.04 1.7 (1.1, 2.6) 0.01
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rs864745 was significantly associated with higher waist 
circumference and FBG as well as lower serum HDL-C 
concentrations.
The JAZF1 polymorphism (rs864745) is within intron 1 
of this gene, which interacts specifically with the ligand-
binding domain of TR4 (known to play roles in lipid 
metabolism and gluconeogenesis) and functions as a 
TR4-selective cofactor that may be involved in mediating 
transcriptional repression by TR4 [14, 19, 20]. However, 
differences in the distribution of risk alleles in various 
ethnic populations have been reported [9–14]. A num-
ber of studies have found an association between certain 
JAZF1 (rs864745) variants and T2DM, whereas others 
have found no association [21]. A Framingham Heart 
Study in whites found that variants of JAZF1 (rs864745) 
are associated with increased risk for T2DM [22], but a 
meta-analysis in a Japanese population identified a nomi-
nal association between JAZF1 (rs864745) variants and 
T2DM [23]. Certain variants in the JAZF1 locus are asso-
ciated abnormal pancreatic β-cell function, which plays 
a role in the pathogenesis of T2DM and are significantly 
associated with impaired glucose regulation as well as 
diabetic nephropathy [14, 19, 20, 24]. Our results are 
similar to those of the above studies showing that JAZF1 
(rs864745) variants are significantly associated with the 
risk of T2DM [9, 11, 13]. A previous study in the same 
local Saudi population showed that other JAZF1 variants 
(rs849134) are associated with increased BMI and T2DM 
risk [1, 25]. In contrast, a study in a Japanese popula-
tion reported no significant association between JAZF1 
polymorphisms (rs864745) and T2DM [26]. McCarthy 
et al. [27] have reported that T2DM-associated variants, 
including those in JAZF1, in healthy populations have a 
predominant effect on insulin secretion, whereas a study 
in nondiabetic Finnish men failed to confirm such an 
association with JAZF1 [28].
The SNP associated with TSPAN8 (rs7961581) have 
been mapped to a region 110-kb upstream of this gene, 
which encodes a widely expressed cell surface glycopro-
tein known to form complexes with integrins. The bind-
ing of 6-integrin to laminin negatively affects pancreatic 
β-cell mass maintenance [20], and SNPs in TSPAN8 may 
influence pancreatic β-cell function [14, 19, 20]. Using the 
results from oral glucose tolerance tests, several studies 
are described an association between certain TSPAN8/
LGR5 variants (rs7961581) and insulin release, reflect-
ing altered β-cell function in T2DM [9, 29, 30]. A signifi-
cant association between TSPAN8/LGR5 rs7961581 and 
T2DM was found in East Asians and European popula-
tions [9, 23]. By contrast, analysis of different TSPAN8 
Table 4 Anthropometric and metabolic parameters according to genotype of JAZF1 and TSPAN8/LGR5 polymorphisms
Data represented by mean ± standard deviation
JAZF1 (rs864745) TSPAN8/LRG5 (rs7961581)
AG + GG AA p value TC + CC TT p value
N 474 326 409 391
Age (Years) 49.8 ± 10.1 49.8 ± 10.2 0.99 49.6 ± 9.7 49.9 ± 10.5 0.69
BMI (kg/m2) 29.9 ± 5.7 29.8 ± 5.9 0.90 29.8 ± 5.8 29.9 ± 5.8 0.81
Waist (cm) 93.8 ± 20.4 89.8 ± 22.1 0.04 92.5 ± 20.3 94.1 ± 21.1 0.28
Systolic BP (mmHg) 119.7 ± 10.8 119.5 ± 10.3 0.83 120.1 ± 10.9 119.2 ± 10.5 0.21
Diastolic BP (mmHg) 77.0 ± 6.7 76.8 ± 6.2 0.71 77.1 ± 6.7 76.9 ± 6.5 0.70
FBG (mmol/L) 9.3 ± 5.1 8.0 ± 4.7 0.01 9.1 ± 5.1 9.0 ± 5.0 0.76
TG (mmol/L) 1.8 ± 1.1 1.9 ± 1.1 0.84 1.8 ± 1.0 1.9 ± 1.1 0.30
TC (mmol/L) 5.3 ± 1.2 5.5 ± 1.0 0.18 5.4 ± 1.2 5.3 ± 1.1 0.73
HDL‑C (mmol/L) 0.72 ± 0.31 0.79 ± 0.34 0.02 0.73 ± 0.31 0.72 ± 0.32 0.52
LDL‑C (mmol/L) 3.7 ± 0.98 3.7 ± 0.81 0.61 3.7 ± 0.97 3.7 ± 0.94 0.52
Table 5 Evaluation of  risk allele frequencies in  the earlier 
ethnic populations
Region/populations Gene Gene References
Locus JAZF1 TSPAN8/LGR5 Cheng et al. [15]
Risk allele A C Cheng et al. [15]
SNPs rs864745 rs7961581 Cheng et al. [15]
African Americans 72.8 22.4 Cheng et al. [15]
Native Hawaiian 73.2 28.9 Cheng et al. [15]
White 51.9 28.6 Cheng et al. [15]
Chinese 76.9 20.8 Zhou et al. [9]
Japanese 78.4 20.5 Omiri et al. [23]
Indians 67.5 35.2 Sanghera et al. [35]
Europeans 50.1 26.9 Zeggini et al. [9]
Latino 61.7 21.3 Cheng et al. [15]
Japanese Americans 77.8 20.3 Cheng et al. [15]
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variants (rs7961581) in the present study and rs4760790 
from a previous study [31] in the same population failed 
to show such an association. The discrepancy may be 
explained by the ethnic and allele frequency differences in 
various population. The insufficient study power (12.2 %) 
could also be a probable reason for lacking the associa-
tion between rs7961581 and T2DM in Saudi population.
We examined various clinical and anthropometric 
characteristics in the study subjects and correlated them 
with the various JAZF1 and TSPAN8/LGR5 genotypes 
(i.e., AG +  GG vs. AA and TC +  CC vs. TT). Only the 
AG  +  GG versus AA genotype comparison revealed an 
association with waist circumference, FBG, and HDL-C 
(p < 0.05). T2DM is associated with an increase in total TG 
and a decrease in HDL-C concentrations. Several popula-
tion-based studies have shown that visceral fat accumula-
tion, high levels of TGs, and low levels of HDL-C predict 
the development of T2DM [28, 32]. Indeed, the results 
from our study suggest that subjects with T2DM have 
increased waist circumference and TG concentrations and 
decreased HDL-C levels. To derive further support for the 
role of JAZF1 (rs864745) and TSPAN8/LGR5 (rs7961581) 
variants in T2DM development, we analyzed the distribu-
tion of confounding factors in relation to possible geno-
types. We found the AG + GG genotypes of rs864745 to 
be significantly associated with increased waist circum-
ference, elevated FBG levels, and reduced levels of serum 
HDL-C, suggesting the possible participation of rs864745 
polymorphism in T2DM etiology. The analysis by Hotta 
et al. [32] revealed no association of either polymorphism 
with visceral fat accumulation [19]. There is evidence to 
indicate an association between JAZF1 variants (rs864745) 
and IGR risk, 2-h glucose concentrations, or both [33]. 
Furthermore, An et  al. [22] have reported that JAZF1, 
independently or interactively with other genes, is asso-
ciated with increased T2DM risk and TG/HDL-C ratio 
change across age groups. A study in Finnish men showed 
that JAZF1 variants (rs864745) were nominally associated 
with an increase in blood lipoprotein levels [28]. Results 
from another study show that JAZF1 variants are also 
associated with arteriolosclerosis [34].
The present study has certain limitations that need 
to be taken into account. A major limitation lies in the 
unmatched design of controls and T2DM cases. Control 
subjects were younger and leaner than T2DM patients.
Conclusion
To our knowledge, the current study is the first to deter-
mine the distribution and frequency of rs864745 (JAZF1) 
polymorphisms and their association with T2DM risk, 
increased waist circumference, and decreased HDL-C con-
centrations in a Saudi population. This finding, along with 
those of a previous report [1] emphasize that JAZF1 is a 
genetic susceptibility locus for the development of T2DM 
in Saudi populations. Functional analysis are necessary to 
identify the molecular basis underlying these genetic pre-
dispositions and phenotype application may provide useful 
strategies for predicting T2DM risk in this population.
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